With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Danish diabetes and obesity giant Novo Nordisk (NOV: N) today announced headline results from REDEFINE 2, a Phase III trial ...

Wegovy is not the only product offered through this new platform. NovoCare also lists Novo Nordisk diabetes products as well as the pharma giant’s drugs for growth-related disorders, hemophilia ...